Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

Klaria Pharma Holding AB: Klaria Interim Report Q2 2025

Klaria Pharma Holding
Download udgivelse

Klaria interim report

1 April-30 June 2025

Summary of the interim report

Second quarter of 2025

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 7.1 MSEK (3.6 MSEK)

- Profit after tax amounted to -20.1 MSEK (-12.4 MSEK)

- Earnings per share for the quarter amounted to -0.14 SEK (-0.11 SEK)

- Cash flow from operating activities amounted to -2.3 MSEK (-1.9 MSEK)

- Liquid assets on the balance sheet date amounted to 2.0 MSEK (1.5 MSEK)

- Group equity as of June 30 amounted to -18.4 MSEK (20.8 MSEK)

- Equity in the parent company as of June 30 amounted to 64.9 MSEK 142.6 MSEK)

The period January-June 2025

The group in total

- Net sales 9.0 MSEK (0.1 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 10.5 MSEK (8.2 MSEK)

- Profit after tax amounted to -21.7 MSEK (-24.3 MSEK)

- Earnings per share for the quarter amounted to -0.15 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -1.7 MSEK (-9.8 MSEK)

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.